Paul Tudor Jones's MRNA Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 344,551 shares of Moderna, Inc. (MRNA) worth $8.9 M, representing 0.02% of the portfolio. First purchased in 2020-Q3, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in MRNA, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 219,273 shares. Largest reduction occurred in Q3 2025, reducing 191,114 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Moderna (MRNA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Moderna (MRNA) Trades by Paul Tudor Jones
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2020 | +8,238 | New Buy | 8,238 | $70.77 |
| Q4 2020 | +1,707 | Add 20.72% | 9,945 | $104.47 |
| Q1 2021 | +18,821 | Add 189.25% | 28,766 | $130.95 |
| Q2 2021 | -19,487 | Reduce 67.74% | 9,279 | $234.94 |
| Q3 2021 | +14,618 | Add 157.54% | 23,897 | $384.86 |
| Q4 2021 | -14,215 | Reduce 59.48% | 9,682 | $253.98 |
| Q1 2022 | -3,849 | Reduce 39.75% | 5,833 | $172.30 |
| Q2 2022 | +8,502 | Add 145.76% | 14,335 | $142.87 |
| Q3 2022 | +22,026 | Add 153.65% | 36,361 | $118.26 |
| Q4 2022 | -26,582 | Reduce 73.11% | 9,779 | $0.18 |
| Q1 2023 | -9,779 | Sold Out | 9,779 | $0.00 |
| Q2 2024 | +124,335 | New Buy | 124,335 | $118.75 |
| Q3 2024 | +28,763 | Add 23.13% | 153,098 | $66.83 |
| Q4 2024 | +200,767 | Add 131.14% | 353,865 | $41.58 |
| Q1 2025 | -37,473 | Reduce 10.59% | 316,392 | $28.35 |
| Q2 2025 | +219,273 | Add 69.30% | 535,665 | $27.59 |
| Q3 2025 | -191,114 | Reduce 35.68% | 344,551 | $25.83 |
Paul Tudor Jones's Moderna Investment FAQs
Paul Tudor Jones first purchased Moderna, Inc. (MRNA) in Q3 2020, acquiring 8,238 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Moderna, Inc. (MRNA) for 21 quarters since Q3 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's largest addition to Moderna, Inc. (MRNA) was in Q2 2025, adding 535,665 shares worth $14.78 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 344,551 shares of Moderna, Inc. (MRNA), valued at approximately $8.9 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Moderna, Inc. (MRNA) represents approximately 0.02% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's peak holding in Moderna, Inc. (MRNA) was 535,665 shares, as reported at the end of Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.